Table 1.
Characteristics of 2888 patients in the Chicago multiethnic epidemiologic cohort of breast cancer study*
| Characteristic | White | Black | Asian | Hispanic | P |
|---|---|---|---|---|---|
| N | 1575 | 1106 | 126 | 81 | |
| Age at diagnosis, n (%) | |||||
| < 40 | 147 (9.3) | 86 (7.8) | 17 (13.5) | 15 (18.5) | < 0.001 |
| 40–49 | 432 (27.4) | 191 (17.3) | 48 (38.1) | 23 (28.4) | |
| -59 | 463 (29.4) | 262 (23.7) | 25 (19.8) | 14 (17.3) | |
| 60–69 | 334 (21.2) | 262 (23.7) | 25 (19.8) | 15 (18.5) | |
| 70+ | 199 (12.6) | 305 (27.6) | 11 (8.7) | 14 (17.3) | |
| Mean (SD) | 54.7 (12.3) | 59.6 (13.9) | 51.1 (12.5) | 53.8 (14.5) | < 0.001 |
| Smoking status, n (%) | |||||
| Never smoker | 968 (63.5) | 597 (55.2) | 105 (90.5) | 48 (62.3) | < 0.001 |
| Previous smoker | 416 (27.3) | 313 (29.0) | 9 (7.8) | 23 (29.9) | |
| Current smoker | 140 (9.2) | 171 (15.8) | 2 (1.7) | 6 (7.8) | |
| Insurance status, n (%) | |||||
| No | 7 (0.4) | 2 (0.2) | 0 (0.0) | 1 (1.2) | < 0.001 |
| Private | 1149 (73.0) | 433 (39.2) | 95 (75.4) | 52 (64.2) | |
| Medicaid | 37 (2.3) | 166 (15.0) | 4 (3.2) | 5 (6.2) | |
| Medicare | 346 (22.0) | 476 (43.0) | 25 (19.8) | 22 (27.2) | |
| Other/unknown | 36 (2.3) | 29 (2.6) | 2 (1.6) | 1 (1.2) | |
| Carlson comorbidity index, n (%) | |||||
| 0 | 1318 (83.7) | 762 (68.9) | 108 (85.7) | 63 (77.8) | < 0.001 |
| 1 | 114 (7.2) | 134 (12.1) | 11 (8.7) | 6 (7.4) | |
| 2 | 115 (7.3) | 132 (11.9) | 4 (3.2) | 11 (13.6) | |
| 3 | 28 (1.8) | 78 (7.1) | 3 (2.4) | 1 (1.2) | |
| Tumor stage, n (%) | |||||
| 0 | 263 (16.7) | 195 (17.6) | 24 (19.0) | 9 (11.1) | 0.097 |
| 1 | 628 (39.9) | 372 (33.6) | 42 (33.3) | 30 (37.0) | |
| 2 | 505 (32.1) | 391 (35.4) | 43 (34.1) | 30 (37.0) | |
| 3 | 179 (11.4) | 148 (13.4) | 17 (13.5) | 12 (14.8) | |
| Estrogen receptor, n (%) | |||||
| Negative | 284 (19.2) | 307 (30.3) | 16 (13.6) | 20 (25.3) | < 0.001 |
| Positive | 1193 (80.8) | 706 (69.7) | 102 (86.4) | 59 (74.7) | |
| Progesterone receptor, n (%) | |||||
| Negative | 458 (31.1) | 436 (43.0) | 29 (24.6) | 26 (32.9) | < 0.001 |
| Positive | 1016 (68.9) | 578 (57.0) | 89 (75.4) | 53 (67.1) | |
| Her2 status, n (%) | |||||
| Negative | 1051 (83.7) | 734 (83.1) | 76 (74.5) | 62 (87.3) | 0.084 |
| Positive | 204 (16.3) | 149 (16.9) | 26 (25.5) | 9 (12.7) | |
| Molecular subtype, n (%) | |||||
| ER/PR+, her2- | 884 (70.4) | 511 (57.9) | 68 (66.7) | 49 (69.0) | < 0.001 |
| ER/PR+, her2+ | 128 (10.2) | 90 (10.2) | 18 (17.6) | 6 (8.5) | |
| ER/PR-, her2+ | 76 (6.1) | 58 (6.6) | 8 (7.8) | 3 (4.2) | |
| Triple negative | 167 (13.3) | 223 (25.3) | 8 (7.8) | 13 (18.3) | |
| Histologic grade, n (%) | |||||
| 1 | 230 (15.6) | 134 (12.8) | 21 (17.8) | 9 (11.5) | < 0.001 |
| 2 | 742 (50.3) | 456 (43.6) | 61 (51.7) | 41 (52.6) | |
| 3 | 504 (34.1) | 456 (43.6) | 36 (30.5) | 28 (35.9) | |
| Type of surgery, n (%) | |||||
| No surgery | 13 (0.8) | 12 (1.1) | 0 (0.0) | 0 (0.0) | < 0.001 |
| Breast conserving surgery | 913 (58.7) | 683 (65.1) | 62 (49.6) | 45 (57.7) | |
| Mastectomy | 629 (40.5) | 354 (33.8) | 63 (50.4) | 33 (42.3) | |
| Chemotherapy, n (%) | |||||
| No | 881 (55.9) | 586 (53.0) | 71 (56.3) | 39 (48.1) | 0.28 |
| Yes | 694 (44.1) | 520 (47.0) | 55 (43.7) | 42 (51.9) | |
| Hormonal therapy, n (%) | |||||
| No | 495 (31.4) | 462 (41.8) | 27 (21.4) | 28 (34.6) | < 0.001 |
| Yes | 1080 (68.6) | 644 (58.2) | 99 (78.6) | 53 (65.4) | |
| Radiotherapy, n (%) | |||||
| No | 657 (41.7) | 437 (39.5) | 63 (50.0) | 28 (34.6) | 0.074 |
| Yes | 918 (58.3) | 669 (60.5) | 63 (50.0) | 53 (65.4) | |
| BMI at baseline, n (%) | |||||
| Underweight | 19 (1.4) | 4 (0.5) | 2 (2.0) | 0 (0.0) | < 0.001 |
| Normal weight | 548 (41.6) | 143 (16.9) | 58 (58.6) | 13 (22.4) | |
| Overweight | 388 (29.5) | 261 (30.9) | 28 (28.3) | 30 (51.7) | |
| Obese | 362 (27.5) | 438 (51.8) | 11 (11.1) | 15 (25.9) | |
| Mean (SD) | 27.5 (6.4) | 31.5 (7.3) | 24.6 (4.3) | 28.7 (6.2) | < 0.001 |
*Number (%) are presented if not otherwise specified and numbers are not added up to total due to missing data. In particular, Her2 data were collected for few patients with stage 0 tumors
Abbreviation: BMI body mass index, SD standard deviation, ER estrogen receptor, PR progesterone receptor